Neuroinflammation-induced deposition in the APPV717F acceleration of amyloid transgenic mouse

It has been postulated that neuroinflammation plays a critical role in the pathogenesis of Alzheimer's disease (AD). To directly test whether an inflammatory stimulus can accelerate amyloid deposition in vivo, we chronically administered the bacterial endotoxin, lipopolysaccharide (LPS), intracerebroventricularly (i.c.v.) to 2-month-old APP(V717F+/+) transgenic (TG) mice, which overexpress a mutant human amyloid precursor protein (APP 717V-F) with or without apolipoprotein E (apoE) for 2 weeks. Two weeks following central LIPS administration a striking global reactive astrocytosis with increased GFAP immunoreactivity was found throughout the brains of all LIPS-treated wild-type and transgenic mice including the contralateral brain hemisphere. Localized microglial activation was also evident from lectin immunostaining adjacent to the cannula track of LPS-treated mice. Quantification of thioflavine-S-positive A beta deposits revealed a marked acceleration of amyloid deposition in LPS-treated AP(PV717F+/+)-apoE(+/+) mice compared to nontreated or vehicle-treated APP(V717+/+)apoE(+/+) mice (P=0.005). By contrast, no amyloid deposits were detected by thioflavine-S staining in LIPS or vehicle-treated apoE-deficient APP(V717F) TG mice. Our data suggest that neuroinflammation can accelerate amyloid deposition in the APP(V717F+/+) mouse model of AD and that this process requires the expression of apoE.